SHANGHAI, China, May 27, 2026
Dizal, a biopharmaceutical company focused on developing targeted oncology therapies, has announced that China’s National Medical Products Administration (NMPA) has accepted and granted Priority Review to the New Drug Application (NDA) for ZEGFROVY® (sunvozertinib) as a first-line treatment for patients with EGFR exon 20 insertion-mutated non-small cell lung cancer (NSCLC). The regulatory milestone marks another major advancement for precision oncology in lung cancer and positions ZEGFROVY as a potential chemotherapy-free oral treatment option for a patient population with significant unmet medical needs.
The application is supported by positive findings from the global WU-KONG28 Phase 3 clinical study, a multinational randomized trial evaluating ZEGFROVY against platinum-based chemotherapy regimens in treatment-naïve patients with advanced EGFR exon20 insertion-mutated NSCLC. According to Dizal, the study achieved its primary endpoint by demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS). Detailed study data are scheduled to be presented as a late-breaking oral presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
ZEGFROVY Targets Difficult-to-Treat EGFR Mutations
EGFR exon 20 insertion mutations represent one of the most challenging subtypes of non-small cell lung cancer due to their molecular heterogeneity and historically limited responsiveness to conventional EGFR-targeted therapies. Current first-line treatment approaches for these patients primarily rely on platinum-based chemotherapy combinations, leaving substantial demand for more effective targeted oral therapies capable of improving long-term disease control and patient quality of life.
According to Dizal, no oral targeted therapies have yet received global approval specifically for first-line treatment of EGFR exon20 insertion-mutated NSCLC. The company believes ZEGFROVY may help address this major treatment gap by providing a highly selective oral therapy designed specifically for these mutations. The investigational therapy previously received Breakthrough Therapy Designations (BTDs) from both the U.S. Food and Drug Administration (FDA) and China’s Center for Drug Evaluation (CDE) for treatment-naïve patients with EGFR exon20 insertion-positive NSCLC.
Advertisement
Dr. Xiaolin Zhang, Chief Executive Officer of Dizal, stated that the latest NDA acceptance and Priority Review designation represent an important step toward expanding global access to ZEGFROVY for underserved lung cancer patients. He emphasized that the positive WU-KONG28 findings support the therapy’s potential to become a practice-changing treatment option in first-line EGFR exon20 insertion NSCLC.
Global Regulatory Momentum Expands for ZEGFROVY
ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists and engineered to target a broad spectrum of EGFR mutations while maintaining selectivity against wild-type EGFR. The therapy has already received approvals in both China and the United States for adult patients with locally advanced or metastatic EGFR exon20 insertion-mutated NSCLC whose disease progressed following platinum-based chemotherapy.
The current supplemental NDA seeks expansion into the first-line treatment setting, potentially allowing newly diagnosed patients to receive targeted oral therapy earlier in disease management before chemotherapy exposure. Dizal confirmed that additional global regulatory submissions are being prepared for other international health authorities as the company expands commercialization efforts worldwide.
In addition to EGFR exon20 insertion mutations, ZEGFROVY has also demonstrated encouraging anti-tumor activity against several other EGFR mutation subtypes, including sensitizing mutations, T790M mutations, uncommon EGFR variants, and HER2 exon20 insertion mutations. Clinical studies have additionally shown that the therapy maintains a manageable safety profile, with most treatment-emergent adverse events classified as mild to moderate and clinically manageable.
Precision Oncology Continues Transforming Lung Cancer Care
The rapid advancement of targeted therapies such as ZEGFROVY reflects broader global momentum within precision oncology, where treatments are increasingly tailored to specific molecular drivers of cancer. Lung cancer remains one of the world’s leading causes of cancer-related mortality, and molecular testing has become increasingly important for identifying patients eligible for personalized targeted therapies.
Industry analysts believe EGFR exon20 insertion-mutated NSCLC represents one of the next major frontiers in targeted lung cancer treatment development due to the historically limited efficacy of older-generation EGFR inhibitors in this patient population. If approved for first-line use, ZEGFROVY could significantly reshape treatment strategies for newly diagnosed patients while further strengthening Dizal’s position within the global precision oncology market.
Source: Dizal press release
